Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 7Gynecologic 5Breast 4Genitourinary 2Gastrointestinal 2Head & Neck 1CNS 1

Conditions

Breast Neoplasms 4Breast Neoplasms, Male 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
paclitaxel poliglumex × Breast × Clear all
NCT01227408 2017-05-02

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

University of Southern California

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT00265733 2016-12-06

Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
48 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00270907 2013-02-13

CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
13 enrolled
Breast

Breast Neoplasms

NCT00148707 2007-12-21

Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
45 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡